Drugs / AZD2962
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07064122 | Nov 2025 → Oct 2028 expected | hematopoietic and lymphoid cell neoplasm | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD2962 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07064122 ↗ |
| Route | Oral | “AZD2962 will be administered orally once daily.” NCT07064122 ↗ |